TCGA-05-4424-01A-22R-1858-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.400
- ANDROGEN_RESPONSE+0.390
- PROTEIN_SECRETION+0.370
- MITOTIC_SPINDLE+0.360
- CHOLESTEROL_HOMEOSTASIS+0.330
- INTERFERON_ALPHA_RESPONSE+0.320
- COMPLEMENT+0.310
- UV_RESPONSE_DN+0.310
- KRAS_SIGNALING_UP+0.270
- NOTCH_SIGNALING+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.320
- PANCREAS_BETA_CELLS-0.270
- DNA_REPAIR-0.250
- P53_PATHWAY-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- OXIDATIVE_PHOSPHORYLATION-0.200
- TNFA_SIGNALING_VIA_NFKB-0.140
- MYC_TARGETS_V1-0.120
- HYPOXIA-0.060
- KRAS_SIGNALING_DN-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3280 | Med | Medulloblastoma | 0.744 |
| 2 | SRR934773 | — | — | 0.722 |
| 3 | SRR934850 | — | — | 0.715 |
| 4 | MNG1023 | — | — | 0.709 |
| 5 | TCGA-91-6828-01A-11R-1858-07 | — | cohortA3 | 0.708 |
| 6 | TCGA-44-6775-01A-11R-A278-07 | — | cohortMD2 | 0.706 |
| 7 | TCGA-GC-A3OO-01A-11R-A22U-07 | — | — | 0.705 |
| 8 | MNG1193 | — | — | 0.704 |
| 9 | TCGA-BA-5151-01A-01R-1436-07 | — | — | 0.703 |
| 10 | 32CED7C6-C413-4B5C-8A49-8AA2C97E582D | — | — | 0.702 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |